Clinical Trial: A Phase I/IIA Open Label Case Study Clinical Trial Evaluating the Safety and Preliminary Efficacy of ELU42, a Small Molecule Wnt Signaling Modulator, in the Treatment of Diabetic Foot Ulcers

U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07396376) titled 'A Phase I/IIA Open Label Case Study Clinical Trial Evaluating the Safety and Preliminary Efficacy of ELU42, a Small Molecule Wnt Signaling Modulator, in the Treatment of Diabetic Foot Ulcers' on Feb. 02.

Brief Summary: ELU42 01 01 (SuperHealer42) is a Phase I/IIA open label study sponsored by Eluciderm, Inc. that evaluates the safety and preliminary effectiveness of ELU42, a topical small molecule designed to modulate Wnt signaling, for the treatment of chronic diabetic foot ulcers (DFU). ELU42 combines a tankyrase inhibitor (XAV939) with a novel derivatized hyaluronic acid excipient (DHA77) and is applied as a topical spray to the ...